Literature DB >> 26009642

Heterogeneity in stabilization phenomena in FLT PET images of canines.

Urban Simoncic1, Robert Jeraj.   

Abstract

3'-((18)F)fluoro-3'-deoxy-L-thymidine (FLT) is a PET marker of cellular proliferation. Its tissue uptake rate is often quantified with a Standardized Uptake Value (SUV), although kinetic analysis provides a more accurate quantification. The purpose of this study is to investigate the heterogeneity in FLT stabilization phenomena. The study was done on 15 canines with spontaneously occurring sinonasal tumours. They were imaged dynamically for 90 min with FLT PET/CT twice; before and during the radiotherapy. Images were analyzed for kinetics on a voxel basis through compartmental analysis. Stabilization curves were calculated as a time-dependant correlation between the time-dependant SUV and the kinetic parameters (voxel values within the tumour were correlated). Stabilization curves were analyzed for stabilization speed, maximal correlation and correlation decrease following the maximal correlation. These stabilization parameters were correlated with the region-averaged kinetic parameters. The FLT SUV was highly correlated with vasculature fraction immediately post-injection, followed by maximum in correlation with the perfusion/permeability. At later times post-injection the FLT SUV was highly correlated (Pearson correlation coefficient above 0.95) with the FLT influx parameter for cases with tumour-averaged SUV(30-50 min) above 2, while others were indeterminate (correlation coefficients from 0.1 to 0.97). All cases with highly correlated SUV and FLT influx parameter had correlation coefficient within 0.5% of its maximum in the period of 30-50 min post-injection. Stabilization time was inversely proportional to the FLT influx rate. Correlation between the FLT SUV and FLT influx parameter dropped at later times post-injection with drop being proportional to the dephosphorylation rate. The FLT was found to be metabolically stable in canines. FLT PET imaging protocol should define minimal and maximal FLT uptake period, which would be 30-50 min for our patients. Additionally, kinetic analysis should be used when low FLT avidity is expected. Low SUVs should be treated with great caution.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 26009642      PMCID: PMC4441216          DOI: 10.1088/0031-9155/59/24/7937

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  29 in total

1.  Anatomy of SUV. Standardized uptake value.

Authors:  S C Huang
Journal:  Nucl Med Biol       Date:  2000-10       Impact factor: 2.408

2.  Shortened PET data acquisition protocol for the quantification of 18F-FDG kinetics.

Authors:  Ludwig G Strauss; Antonia Dimitrakopoulou-Strauss; Uwe Haberkorn
Journal:  J Nucl Med       Date:  2003-12       Impact factor: 10.057

3.  SUV: standard uptake or silly useless value?

Authors:  J W Keyes
Journal:  J Nucl Med       Date:  1995-10       Impact factor: 10.057

4.  In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors.

Authors:  Hubert Vesselle; John Grierson; Mark Muzi; Jeffrey M Pugsley; Rodney A Schmidt; Peter Rabinowitz; Lanell M Peterson; Eric Vallières; Douglas E Wood
Journal:  Clin Cancer Res       Date:  2002-11       Impact factor: 12.531

5.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

Authors:  H Young; R Baum; U Cremerius; K Herholz; O Hoekstra; A A Lammertsma; J Pruim; P Price
Journal:  Eur J Cancer       Date:  1999-12       Impact factor: 9.162

6.  3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.

Authors:  Henryk Barthel; Marcel C Cleij; David R Collingridge; O Clyde Hutchinson; Safiye Osman; Qimin He; Sajinder K Luthra; Frank Brady; Pat M Price; Eric O Aboagye
Journal:  Cancer Res       Date:  2003-07-01       Impact factor: 12.701

7.  Kinetic analysis of 2-[carbon-11]thymidine PET imaging studies: compartmental model and mathematical analysis.

Authors:  D A Mankoff; A F Shields; M M Graham; J M Link; J F Eary; K A Krohn
Journal:  J Nucl Med       Date:  1998-06       Impact factor: 10.057

8.  [18F]FLT PET for diagnosis and staging of thoracic tumours.

Authors:  Helmut Dittmann; Bernhard Matthias Dohmen; Frank Paulsen; Kai Eichhorn; Susanne Martina Eschmann; Marius Horger; Manfred Wehrmann; Hans Juergen Machulla; Roland Bares
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-07-26       Impact factor: 9.236

9.  PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study.

Authors:  Brigitte Smyczek-Gargya; Nikos Fersis; Helmut Dittmann; Ulrich Vogel; Gerald Reischl; Hans-Juergen Machulla; Diethelm Wallwiener; Roland Bares; Bernhard M Dohmen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02-19       Impact factor: 9.236

10.  Comparison of methodologies for the in vivo assessment of 18FLT utilisation in colorectal cancer.

Authors:  D Visvikis; D Francis; R Mulligan; D C Costa; I Croasdale; S K Luthra; I Taylor; P J Ell
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

View more
  1 in total

1.  Evaluation of 18F-fluorothymidine positron emission tomography ([18F]FLT-PET/CT) methodology in assessing early response to chemotherapy in patients with gastro-oesophageal cancer.

Authors:  R Sharma; P Mapelli; G B Hanna; R Goldin; D Power; A Al-Nahhas; S Merchant; R Ramaswami; A Challapalli; T Barwick; E O Aboagye
Journal:  EJNMMI Res       Date:  2016-11-16       Impact factor: 3.138

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.